Compare ATGL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | MGNX |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 220.6M |
| IPO Year | 2023 | 2013 |
| Metric | ATGL | MGNX |
|---|---|---|
| Price | $11.00 | $4.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 1.3K | ★ 1.3M |
| Earning Date | 01-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.01 | $1.30 |
| 52 Week High | $50.00 | $5.08 |
| Indicator | ATGL | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 49.98 |
| Support Level | $10.52 | $1.49 |
| Resistance Level | $16.08 | $4.55 |
| Average True Range (ATR) | 0.82 | 0.38 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 8.49 | 36.57 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.